BKD
Brookdale Senior Living Inc.
BKD has a slight edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BKD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
BKD's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BKD PE Valuation
BKD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 460x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BKD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BKD to return to profit, with revenue holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BKD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.17 | +$1.14 |
| Q2 2026 | -$0.59 | +$0.46 |
| Q1 2026 | -$0.87 | +$0.17 |
| Q4 2025 | -$1.12 | -$0.23 |
| Q3 2025 | -$1.31 | -$0.39 |
| Q2 2025 | -$1.05 | -$0.13 |
| Q1 2025 | -$1.04 | -$0.27 |
| Q4 2024 | -$0.89 | -$0.05 |
BKD is still losing money, but far less than before: $0.17 per share over the past year, against $2.15 at its worst in early 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BKD on earnings quality, reporting a profit while its opponent remains loss making.
BKD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $712.1M | -12% |
| Q2 2026 | $718.6M | -12% |
| Q1 2026 | $764.9M | -6% |
| Q4 2025 | $754.1M | -3.4% |
| Q3 2025 | $813.2M | +3.7% |
| Q2 2025 | $812.9M | +4.6% |
| Q1 2025 | $813.9M | +4% |
| Q4 2024 | $780.9M | +3.5% |
BKD's revenue has slid since its 2020 peak: $712M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +12 points |
| Q2 2026 | 12% | +10 points |
| Q1 2026 | 6.8% | +3.1 points |
| Q4 2025 | 3% | +3.3 points |
| Q3 2025 | -6.6% | -7.9 points |
| Q2 2025 | 1.8% | -0.6 points |
| Q1 2025 | 3.6% | +1.2 points |
| Q4 2024 | -0.3% | +2.9 points |
BKD's operating margin was 5.8% last quarter, up 12 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BKD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BKD on profitability, with a higher operating margin.
BKD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.7M | -26% |
| Q2 2026 | $43.5M | +49% |
| Q1 2026 | -$25.6M | -$7.2M |
| Q4 2025 | -$29.1M | -$24M |
| Q3 2025 | $34.9M | +204% |
| Q2 2025 | $29.1M | +610% |
| Q1 2025 | -$18.4M | +$27.1M |
| Q4 2024 | -$5.1M | +$24.1M |
BKD has burned cash in most quarters: $15M over the past year, down 64% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
BKD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -4.7M shares |
| 1 year | +0.7% | +1.7M shares |
| 3 years | +6.1% | +13.7M shares |
| 5 years | +22% | +42.9M shares |
| Available history | +29% | +53.2M shares |
BKD has 239M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $18.1M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BKD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BKD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.0x | High |
| Q2 2026 | 9.1x | High |
| Q1 2026 | 10.6x | High |
| Q4 2025 | 10.7x | High |
| Q3 2025 | 10.9x | High |
| Q2 2025 | 9.5x | High |
| Q1 2025 | 9.6x | High |
| Q4 2024 | 9.2x | High |
BKD's net debt is about 8.0 years of its operating earnings (EBITDA), down from 11 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over BKD on leverage, with a lower net debt burden relative to earnings.
BKD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.0 | Oversold |
| Stochastic | 6.9 | Oversold |
BKD's weekly RSI is 29 (oversold) and its Stochastic is 7 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BKD PE vs Healthcare Sector
| Metric | BKD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BKD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BKD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 11% below |
| 20 week MA | $12.1 | 26% below |
| 50 week MA | $12.8 | 30% below |
| 100 week MA | $9.91 | 9.6% below |
| 200 week MA | $7.54 | 19% above |
BKD has fallen below most of its moving averages, though it's still 19% above its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
BKD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.01 | $4.21 | -40% |
| 2021 | $4.21 | $5.17 | +23% |
| 2022 | $5.17 | $2.71 | -48% |
| 2023 | $2.71 | $5.82 | +115% |
| 2024 | $5.82 | $5.07 | -13% |
| 2025 | $5.07 | $10.9 | +115% |
| 2026 YTD | $10.9 | $8.96 | -18% |
BKD has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.